Hemophagocytic Lymphohistiocytosis: Types, Causes, Symptoms, And More

Hemophagocytic lymphohistiocytosis, usually shortened to HLH, is one of those medical terms that sounds like it should come with a pronunciation trophy and a free cup of coffee. But behind the tongue twister is a very serious condition. HLH is a rare, life-threatening syndrome in which the immune system becomes dangerously overactive and starts causing damage instead of protection.

In simple terms, the body’s defense system slams on the gas, loses the brakes, and begins attacking healthy tissues. That runaway inflammation can affect the bone marrow, liver, spleen, brain, lungs, and other organs. Because the symptoms can mimic infections, blood cancers, or severe autoimmune flares, HLH is often difficult to spot early. And with HLH, early recognition matters a lot.

This guide explains the types of hemophagocytic lymphohistiocytosis, what causes it, the most common warning signs, how doctors diagnose it, what treatment may involve, and what living with HLH can actually feel like for patients and families.

What Is Hemophagocytic Lymphohistiocytosis?

HLH is a severe hyperinflammatory disorder. It happens when certain immune cells, especially T cells, natural killer (NK) cells, and macrophages, become abnormally activated. Instead of calming down after fighting a threat, they keep pumping out inflammatory chemicals called cytokines. That can create what many clinicians describe as a cytokine storm.

As this inflammatory cascade builds, the body can develop persistent fever, low blood counts, liver and spleen enlargement, clotting problems, neurologic symptoms, and even organ failure. HLH may occur in infants and young children, but it can also affect teens and adults. In children, inherited disease is an important concern. In adults, HLH more often appears as a complication of another serious condition.

Types of HLH

Primary HLH

Primary HLH, also called familial HLH, is linked to inherited genetic variants that disrupt how the immune system shuts itself off. Several genes have been associated with this form, including PRF1, UNC13D, STX11, STXBP2, and others. When these genes do not work properly, immune cells may struggle to kill infected or abnormal target cells, so the immune response keeps escalating.

Primary HLH often appears in infancy or early childhood, but not always. Some people present later, especially if the underlying genetic change allows a little residual immune function. A common pattern is that a child seems well until an infection acts like a spark in a dry forest and sets off full-blown inflammation.

Secondary HLH

Secondary HLH, also known as acquired HLH, is triggered by another illness or immune stressor. It is more common than primary HLH. In many patients, HLH develops in the setting of:

• Viral infections, especially Epstein-Barr virus (EBV)
• Other infections, including bacterial, fungal, or parasitic disease
• Cancers, particularly lymphomas and other blood-related malignancies
• Autoimmune or autoinflammatory diseases
• Immune dysfunction or immunodeficiency states

In rheumatology, a related syndrome called macrophage activation syndrome (MAS) is often considered part of the HLH spectrum. MAS can occur in conditions such as systemic juvenile idiopathic arthritis or adult Still’s disease. Different label, same terrifying immune overreaction.

What Causes HLH?

The big-picture cause of HLH is immune dysregulation. The more specific cause depends on the type.

Causes of Primary HLH

In primary HLH, the root problem is genetic. Certain inherited variants affect proteins needed for immune cells to perform controlled cell killing and then deactivate appropriately. Without that control, inflammation can spiral. Family history may raise suspicion, but some families have no known history at all.

Causes of Secondary HLH

In secondary HLH, the immune system is pushed into overdrive by a trigger. EBV is one of the best-known infectious triggers. Other cases are associated with leukemia, lymphoma, autoimmune disease, or severe systemic infection. In adults, doctors often spend a lot of time looking for the underlying driver, because treatment is not just about calming inflammation. It is also about finding and treating what lit the fuse in the first place.

That is why HLH can be so challenging: it is not one neat disease with one neat cause. It is more like an emergency alarm with multiple possible reasons for going off.

Common Symptoms of Hemophagocytic Lymphohistiocytosis

HLH symptoms can start subtly and then worsen quickly. Some look like bad flu symptoms. Others resemble sepsis, leukemia, liver disease, or a severe autoimmune flare. Common symptoms and signs include:

• Persistent high fever
• Enlarged spleen and sometimes enlarged liver
• Swollen lymph nodes
• Rash
• Extreme fatigue or weakness
• Pale skin from anemia
• Easy bruising or bleeding from low platelets
• Jaundice
• Shortness of breath or lung involvement
• Headache, irritability, confusion, seizures, or other neurologic symptoms

Blood tests often show cytopenias, meaning low levels of red blood cells, white blood cells, platelets, or a combination of all three. Ferritin, a marker that stores iron, may become dramatically elevated. Doctors may also see high triglycerides, low fibrinogen, abnormal liver tests, and markers suggesting intense immune activation.

One important point: HLH does not always arrive wearing a giant neon sign that says “I am HLH.” It often arrives disguised as something else. That is one reason delays in diagnosis can happen.

How HLH Is Diagnosed

Diagnosing hemophagocytic lymphohistiocytosis usually requires a mix of clinical suspicion, lab work, and investigation for an underlying cause. There is no single quick-and-easy test that settles every case.

Doctors often use the classic HLH-2004 diagnostic criteria. A diagnosis may be supported if a patient has a known HLH-related genetic defect or meets at least five of eight criteria, which include:

• Fever
• Splenomegaly
• Cytopenias affecting at least two blood cell lines
• High triglycerides and/or low fibrinogen
• Hemophagocytosis seen in bone marrow or other tissue
• Low or absent NK-cell activity
• Elevated ferritin
• Elevated soluble IL-2 receptor (sCD25)

Bone marrow testing may show hemophagocytosis, which means immune cells engulfing other blood cells. But here is the catch: that finding can support the diagnosis, yet its absence does not rule HLH out. Doctors may also order imaging, infectious disease tests, cancer workups, rheumatologic testing, and genetic testing when primary HLH is suspected.

In children with a strong family history, early-onset disease, or recurrent episodes, genetic evaluation becomes especially important. In adults, physicians often have to sort through a complicated mess of infection, cancer, inflammation, and organ dysfunction before HLH becomes obvious.

Treatment for HLH

HLH treatment has two major goals: stop the immune system from causing further damage and identify the underlying trigger. Treatment should be directed by specialists familiar with HLH whenever possible, because this is not a “let’s see how you feel next month” condition.

Initial Treatment

Many patients need rapid treatment with medications that suppress inflammation and dampen the abnormal immune response. Depending on the clinical situation, therapy may include:

• Corticosteroids such as dexamethasone
• Etoposide, especially in severe or protocol-based treatment
• Cyclosporine in select cases
• Supportive care, including transfusions, antibiotics, ICU care, or organ support

Doctors also treat the trigger whenever possible. That may mean antivirals or targeted treatment for infection, chemotherapy for lymphoma, or disease-specific therapy for autoimmune disease. In some patients, calming the trigger and calming the immune system have to happen at the same time, which is a bit like repairing the plumbing while the basement is still flooding.

Targeted and Newer Therapies

More targeted approaches are increasingly part of the HLH conversation. Emapalumab (Gamifant), an interferon-gamma blocking monoclonal antibody, is FDA-approved in the United States for certain adults and children with primary HLH that is refractory, recurrent, progressive, or intolerant of conventional therapy. More recently, FDA labeling has also included certain patients with HLH/MAS in known or suspected Still’s disease.

Some specialty centers also use agents such as ruxolitinib or other cytokine-targeting therapies in selected patients, especially when the inflammatory pathway needs a more customized approach. These decisions are highly individualized.

Stem Cell Transplant

For many patients with familial or persistent primary HLH, the best chance for long-term control or cure is an allogeneic hematopoietic stem cell transplant. That transplant replaces the defective immune system with a healthy donor-derived one. It is a major treatment, not a casual Tuesday errand, but it can be lifesaving.

Complications and Outlook

HLH is dangerous because uncontrolled inflammation can affect almost every organ system. Possible complications include liver injury, bleeding, neurologic impairment, respiratory failure, overwhelming infection, and multiorgan failure. Prognosis varies widely depending on how fast the condition is recognized, what triggered it, whether it is primary or secondary, and how well the patient responds to treatment.

Children with inherited HLH often need long-term planning that includes transplant evaluation. Adults with secondary HLH may do better when the underlying trigger is found quickly and treated aggressively. On the other hand, malignancy-associated HLH can be especially difficult and may carry a worse outlook.

That is why persistent fever, enlarged spleen, unexplained low blood counts, and very high ferritin levels should make clinicians think about HLH early. In rare-disease medicine, time is not just money. It is oxygen, organ function, and opportunity.

When to Seek Medical Care

HLH is a medical emergency. Anyone with persistent high fever, severe fatigue, bruising, jaundice, breathing trouble, confusion, seizures, or rapid worsening illness needs prompt medical evaluation. This is especially true when blood counts are low or a patient already has a major risk factor such as lymphoma, EBV infection, Still’s disease, or suspected immune dysfunction.

For families already living with known primary HLH risk, any major fever or sudden decline should be taken seriously and discussed with the care team immediately.

Final Thoughts

Hemophagocytic lymphohistiocytosis is rare, complex, and genuinely frightening, but it is not beyond understanding. The main idea is this: HLH happens when the immune system loses control and creates overwhelming inflammation. There are two main types of HLH, primary and secondary, and the cause can range from inherited genetic variants to infections, cancer, or autoimmune disease. The most important symptoms include persistent fever, enlarged spleen, low blood counts, high ferritin, and signs of organ involvement.

The earlier HLH is suspected, the better the odds of getting the right treatment in time. For patients and families, that means asking questions, staying alert to warning signs, and seeking specialized care quickly. For clinicians, it means keeping HLH on the differential diagnosis list when the puzzle pieces do not fit ordinary explanations.

Experience and Daily Life: What HLH Can Feel Like for Patients and Families

The lived experience of HLH is often a story of speed, uncertainty, and emotional whiplash. One week, a patient may seem to have a stubborn viral illness. The next, they are in the hospital with fevers that will not quit, strange lab results, and a care team using phrases nobody expects to hear over breakfast. For families, HLH can feel like being dropped into the deep end of medicine without a life jacket and then being handed a vocabulary quiz.

Parents of children with primary HLH often describe the earliest stage as confusion. Their child may develop recurrent fevers, swelling, irritability, poor feeding, bruising, or unusual fatigue. At first, it may look like a common infection. Then the blood counts come back low. Then the spleen is enlarged. Then another specialist enters the room. Many families say the hardest part is how quickly the situation changes from “we are watching this closely” to “we need to act now.”

Adults with secondary HLH often experience a different but equally stressful path. Some are already dealing with cancer, autoimmune disease, or a severe infection when HLH enters the picture. They may be exhausted, short of breath, feverish, and mentally foggy, yet still not have a clear explanation for why everything is suddenly getting worse. Several patients describe this period as feeling like their body is “on fire from the inside,” while routine daily tasks become almost impossible. The physical symptoms are one burden. The uncertainty is another.

Hospitalization can be intense. Patients may need repeated blood draws, scans, bone marrow testing, transfusions, IV medications, and careful monitoring for infection or organ complications. Families often bounce between hope and fear many times in a single day. A slightly better ferritin level can feel like a parade. A new fever can feel like the floor giving way again.

When treatment starts working, relief does not always arrive in one dramatic cinematic moment. Sometimes it is small and gradual: the fever curve softens, appetite returns a little, mental clarity improves, the lab numbers start behaving less like rebellious teenagers. Recovery can still be complicated, especially if the patient needs transplant evaluation, prolonged immune suppression, or treatment for the underlying trigger.

Long after the crisis phase, many people carry an emotional aftershock. Parents may become hyperaware of every fever. Adult survivors may struggle with fatigue, anxiety, follow-up appointments, and the challenge of explaining a rare disease to employers, schools, and even friends. “Rare” can be lonely. Support groups, specialty centers, counseling, and clear communication from the medical team can make a real difference.

There is also resilience in these stories. Families learn medical language they never asked to learn. Patients discover patience they did not know they had. Caregivers become expert notebook keepers, medication organizers, and champions for second opinions. No one would volunteer for the HLH experience, but many people come out of it with a deeper sense of urgency about symptoms, a sharper instinct for self-advocacy, and a fierce appreciation for ordinary days.

If there is one thread that runs through most HLH experiences, it is this: people do better when they are heard early, evaluated thoroughly, and treated by teams who recognize that something rare and dangerous may be unfolding. In a disease as complex as HLH, being taken seriously is not just comforting. It can be lifesaving.